- Trials with a EudraCT protocol (112)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (5)
112 result(s) found for: Herpes Virus.
Displaying page 1 of 6.
EudraCT Number: 2019-001572-11 | Sponsor Protocol Number: LLB-2019-01 | Start Date*: 2020-08-05 | |||||||||||||||||||||
Sponsor Name:LABO’LIFE Belgium sprl | |||||||||||||||||||||||
Full Title: Randomized, placebo-controlled, double-blind study to evaluate the efficacy of 2LHERP® in patients with recurrent genital herpes infections. | |||||||||||||||||||||||
Medical condition: Patients presenting recurrent genital herpes infections (4 or more episodes within the 12-months’ period prior to their study entry). | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: BE (Prematurely Ended) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-002135-26 | Sponsor Protocol Number: 4PH/2011/002 | Start Date*: 2012-02-16 | |||||||||||
Sponsor Name:AESCULAPIUS FARMACEUTICI S.R.L. | |||||||||||||
Full Title: Efficacy and Safety of Acyclovir 5 Lipstick (Contra) in Treatment of Skin Infections Provoked by Herpes Simplex. A Randomised, Double-blind, Placebo Controlled, Parallel Group Study. | |||||||||||||
Medical condition: History of recurrent herpes labialis with at least 3 recurrences during the past 12 months and typically (>50% of episodes) associated with prodromal symptoms | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-000182-38 | Sponsor Protocol Number: ACYCLOVIR LP 01/06 | Start Date*: 2007-07-26 | |||||||||||
Sponsor Name:MIPHARM | |||||||||||||
Full Title: EFFICACY AND SAFETY OF A NEW TOPICAL FORMULATION OF ACYCLOVIR GEL (LP) IN THE TREATMENT OF HERPES SIMPLEX LABIALIS A RANDOMIZED, Single-BLIND, MULTICENTER, CONTROLLED CLINICAL TRIAL ve... | |||||||||||||
Medical condition: Subjects with a clinical diagnosis of Herpes Simplex Labialis on the perioral area. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) GB (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003586-35 | Sponsor Protocol Number: 215336 | Start Date*: 2022-01-25 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:GlaxoSmithKline Biologicals SA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: A Phase I/II, observer-blind, randomised, placebo controlled, multi-country study to evaluate reactogenicity, safety, immune response, and efficacy of an HSV-targeted immunotherapy in healthy parti... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Recurrent genital herpes | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: BE (Ongoing) DE (Trial now transitioned) ES (Ongoing) EE (Ongoing) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-005319-30 | Sponsor Protocol Number: 217917 | Start Date*: 2022-11-02 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: A phase 3b, open-label, multi-country, multi-centre, long-term follow-up study of ZOSTER-049 (follow-up of ZOSTER-006/022 studies) to assess the prophylactic efficacy, safety and persistence of imm... | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Vaccination against HZ and its related complications in adults older than 50 years (at the time of primary vaccination). | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: DE (Trial now transitioned) SE (Ongoing) FI (Ongoing) EE (Ongoing) ES (Ongoing) IT (Ongoing) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-005010-12 | Sponsor Protocol Number: CFAM810B2301 | Start Date*: 2007-04-02 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A multicenter, open-label, single-arm study to evaluate the single-dose pharmacokinetics, acceptability and safety of famciclovir oral pediatric formulation in infants 1 month to <1 year of age wit... | |||||||||||||
Medical condition: herpes simplex or varicella zoster virus infections in infants 1 month to <1 year of age | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000549-38 | Sponsor Protocol Number: LIP-01-01 | Start Date*: 2018-01-29 | |||||||||||
Sponsor Name:Laboratorios Ojer Pharma S.L. | |||||||||||||
Full Title: An open-label study to investigate the local tolerability and acceptability of Lipovir® Gel (Acyclovir 5%) compared to Zovirax® Cream (Acyclovir 5%) on patients with Recurrent Herpes Labialis | |||||||||||||
Medical condition: Herpes labialis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-005835-14 | Sponsor Protocol Number: Acyclovir01/08 | Start Date*: 2008-11-26 | |||||||||||
Sponsor Name:MIPHARM | |||||||||||||
Full Title: Efficacy and tolerability of a new topical formulation of Acyclovir gel (Acyclorir Liquipatch) given 3 times/day in the treatment of herpes simplex labialis. An open-label, blind controlled, random... | |||||||||||||
Medical condition: Herpes Simplex Labialis on the perioral area | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-000880-26 | Sponsor Protocol Number: HTX101-02G | Start Date*: 2019-09-03 | |||||||||||
Sponsor Name:Heidelberg ImmunoTherapeutics GmbH | |||||||||||||
Full Title: A Randomized, Double-Blind, Double-Dummy Phase II Study of Single Dose HDIT101 versus Standard of Care Valaciclovir in Patients with Chronic Recurrent Anogenital HSV-2 Infection | |||||||||||||
Medical condition: Chronic recurrent anogenital HSV-2 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-000343-10 | Sponsor Protocol Number: V211-020-00 | Start Date*: 2007-11-20 | |||||||||||
Sponsor Name:Merck & Co., Inc. | |||||||||||||
Full Title: A Phase IV Clinical Trial to Evaluate the Safety and Tolerability of ZOSTAVAX™ in Subjects ≥60 Years of Age | |||||||||||||
Medical condition: Herpes Zoster | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-004020-20 | Sponsor Protocol Number: V211-022 | Start Date*: 2007-12-10 | |||||||||||
Sponsor Name:Merck & Co., Inc. | |||||||||||||
Full Title: A Phase III Clinical Trial to Evaluate the Efficacy, Immunogenicity, Safety and Tolerability of ZOSTAVAX™ in Subjects 50 to 59 Years of Age | |||||||||||||
Medical condition: Herpes Zoster | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) FI (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-020150-34 | Sponsor Protocol Number: V212-001-01 | Start Date*: 2010-10-28 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Study the Safety, Tolerability, Efficacy, and Immunogenicity of V212 in Recipients of Autologous Hematopoiet... | |||||||||||||
Medical condition: Incidence of Herpes Zoster in recipients of Autologous HCTs | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) NL (Completed) ES (Completed) SE (Completed) CZ (Completed) GB (Completed) LT (Completed) IT (Completed) BE (Completed) PT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001451-30 | Sponsor Protocol Number: UMCN-AKF12.07 | Start Date*: 2019-06-17 | |||||||||||
Sponsor Name:Radboud university medical center | |||||||||||||
Full Title: Pharmacokinetics of a new paediatric formulation of valacyclovir used for prophylaxis and treatment of VZV and HSV infections in children, phase II (VALID II) | |||||||||||||
Medical condition: Herpes virus infections, especially Herpes Simplex and Varicella Zoster. | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-023156-89 | Sponsor Protocol Number: V212-011 | Start Date*: 2011-02-24 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp. a subsidiary of Merck & Co., Inc | |||||||||||||
Full Title: Ensayo clínico en fase III, aleatorizado y controlado con placebo para estudiar la seguridad y la eficacia de V212 en pacientes adultos con tumor sólido o neoplasia hematológica. A Phase III Rando... | |||||||||||||
Medical condition: Incidence of Herpes Zoster in adults with solid tumor or hematologic malignancy Incidencia de Herpes Zoster en pacientes adultos con tumor sólido o neoplasia hematológica. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) DE (Completed) CZ (Completed) GB (Completed) SK (Completed) AT (Completed) BE (Completed) EE (Completed) LT (Completed) GR (Completed) BG (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-004316-31 | Sponsor Protocol Number: FPP4-DE-401 | Start Date*: 2009-02-23 | |||||||||||
Sponsor Name:Novartis Consumer Health S.A. | |||||||||||||
Full Title: A randomised, double-blind, vehicle controlled, single centre, parallel group, comparative study of the efficacy of penciclovir 10 mg/g (1%) cream in preventing the appearance of classical lesions ... | |||||||||||||
Medical condition: Cold Sores caused by the herpes simplex virus (HSV) type 1. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004835-19 | Sponsor Protocol Number: 38RC16.015 | Start Date*: 2017-07-20 | |||||||||||
Sponsor Name:University Hospital Grenoble | |||||||||||||
Full Title: Dexamethasone in Herpes Simplex Virus Encephalitis Open label Randomized Controlled Trial with an Observer-blinded evaluation at 6 months | |||||||||||||
Medical condition: HSV encephalitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-002313-11 | Sponsor Protocol Number: V212-009-00 | Start Date*: 2012-01-20 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Phase II Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Immunogenicity of V212 in Adult Patients with Autoimmune Disease | |||||||||||||
Medical condition: Prevention of herpes zoster in adults with autoimmune disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) BE (Completed) EE (Completed) DK (Completed) ES (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-012458-19 | Sponsor Protocol Number: ZTV03C | Start Date*: 2009-10-15 | |||||||||||
Sponsor Name:Sanofi Pasteur MSD S.N.C. | |||||||||||||
Full Title: An open-label, randomised, comparative, multicentre study of the immunogenicity and safety of ZOSTAVAX® when administered by intramuscular route or subcutaneous route to subjects ≥50 years of age | |||||||||||||
Medical condition: Not applicable as Prevention of herpes zoster ("zoster" or shingles) and herpes zoster-related post-herpetic neuralgia (PHN). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000926-24 | Sponsor Protocol Number: HTX101-03L | Start Date*: 2020-08-17 | ||||||||||||||||
Sponsor Name:Heidelberg ImmunoTherapeutics | ||||||||||||||||||
Full Title: A Randomised, Double-Blind Phase II Trial of Topical HDIT101 versus Placebo in Patients with Chronic Recurrent HSV-1 Infection and Orolabial Lesion | ||||||||||||||||||
Medical condition: Chronic Herpes Simplex Virus-1 Infection | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-000344-26 | Sponsor Protocol Number: V211-012-00 | Start Date*: 2007-06-04 | |||||||||||
Sponsor Name:Merck & Co., Inc. | |||||||||||||
Full Title: A Phase III Double-Blind, Randomized Multicenter Study to Evaluate the Safety, Tolerability and Immunogenicity of ZOSTAVAX administered comcomitantly versus Non-concomitantly with PNEUMOVAX 23 in s... | |||||||||||||
Medical condition: herpes zoster, pneumococcal infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) IT (Completed) GB (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.